Updates on the WHO Diagnosis of IDH-mutant Glioma

Overview

Journal J Neurooncol

Publisher Springer

Date 2023 Jan 30

PMID 36717507

Authors

David E Reuss

Affiliations

Soon will be listed here.

Abstract

Purpose: The WHO classification of Tumors of the Central Nervous System represents the international standard classification for brain tumors. In 2021 the 5th edition (WHO CNS5) was published, and this review summarizes the changes regarding IDH-mutant gliomas and discusses unsolved issues and future perspectives.

Methods: This review is based on the 5th edition of the WHO Blue Book of CNS tumors (WHO CNS5) and relevant related papers.

Results: Major changes include taxonomy and nomenclature of IDH-mutant gliomas. Essential and desirable criteria for classification were established considering technical developments. For the first time molecular features are not only relevant for the classification of IDH-mutant gliomas but may impact grading as well.

Conclusion: WHO CNS5 classification moves forward towards a classification which is founded on tumor biology and serves clinical needs. The rapidly increasing knowledge on the molecular landscape of IDH-mutant gliomas is expected to further refine classification and grading in the future.

Citing Articles

ATP1B3 may promote glioma proliferation and migration through MAPK/NF-KB signaling pathway.

Yan Q, Sun Q, Feng Y, Hu Q, Zhu J Front Oncol. 2025; 15:1537687.

PMID: 40027130 PMC: 11868815. DOI: 10.3389/fonc.2025.1537687.

Development and Validation of a Non-Invasive Prediction Model for Glioma-Associated Epilepsy: A Comparative Analysis of Nomogram and Decision Tree.

Zhong Z, Yu H, Tong Y, Li J Int J Gen Med. 2025; 18:1111-1125.

PMID: 40026809 PMC: 11872099. DOI: 10.2147/IJGM.S512814.

Comparative Clinical-Imaging and Histogenetic Analysis Between Astrocytoma IDH-Mutant Grade 4 and Glioblastoma IDH-Wildtype-Is There Really a Worse One?.

Orasanu C, Aschie M, Deacu M, Bosoteanu M, Vamesu S, Enciu M Diagnostics (Basel). 2025; 15(4).

PMID: 40002588 PMC: 11854731. DOI: 10.3390/diagnostics15040438.

Mechanism analysis and targeted therapy of IDH gene mutation in glioma.

Ma X, Sun C, Ding X, Xu J, Zhang Y, Deng T Am J Cancer Res. 2025; 15(1):248-270.

PMID: 39949933 PMC: 11815359. DOI: 10.62347/NSXC2205.

Advances in Glioblastoma Diagnosis: Integrating Genetics, Noninvasive Sampling, and Advanced Imaging.

Gough R, Treffy R, Krucoff M, Desai R Cancers (Basel). 2025; 17(1.

PMID: 39796751 PMC: 11720166. DOI: 10.3390/cancers17010124.

References

von Deimling A, Ono T, Shirahata M, Louis D . Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing. Semin Neurol. 2018; 38(1):19-23. DOI: 10.1055/s-0038-1636430. View

Nasrallah M, Desai A, ORourke D, Surrey L, Stein J . A dual-genotype oligoastrocytoma with histologic, molecular, radiological and time-course features. Acta Neuropathol Commun. 2020; 8(1):115. PMC: 7372861. DOI: 10.1186/s40478-020-00998-3. View

Eckel-Passow J, Lachance D, Molinaro A, Walsh K, Decker P, Sicotte H . Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med. 2015; 372(26):2499-508. PMC: 4489704. DOI: 10.1056/NEJMoa1407279. View

Yoda R, Marxen T, Longo L, Ene C, Wirsching H, Keene C . Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma. J Neuropathol Exp Neurol. 2019; 78(11):1002-1010. DOI: 10.1093/jnen/nlz082. View

Barresi V, Lionti S, Valori L, Gallina G, Caffo M, Rossi S . Dual-Genotype Diffuse Low-Grade Glioma: Is It Really Time to Abandon Oligoastrocytoma As a Distinct Entity?. J Neuropathol Exp Neurol. 2017; 76(5):342-346. DOI: 10.1093/jnen/nlx024. View

Giannini C, Scheithauer B, Weaver A, Burger P, Kros J, Mork S . Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol. 2001; 60(3):248-62. DOI: 10.1093/jnen/60.3.248. View

Dodgshun A, Fukuoka K, Edwards M, Bianchi V, Das A, Sexton-Oates A . Germline-driven replication repair-deficient high-grade gliomas exhibit unique hypomethylation patterns. Acta Neuropathol. 2020; 140(5):765-776. DOI: 10.1007/s00401-020-02209-8. View

Suwala A, Stichel D, Schrimpf D, Kloor M, Wefers A, Reinhardt A . Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. Acta Neuropathol. 2020; 141(1):85-100. PMC: 7785563. DOI: 10.1007/s00401-020-02243-6. View

Capper D, Stichel D, Sahm F, Jones D, Schrimpf D, Sill M . Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathol. 2018; 136(2):181-210. PMC: 6060790. DOI: 10.1007/s00401-018-1879-y. View

10.

Yang R, Shi Z, Zhang Z, Chan A, Aibaidula A, Wang W . IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. Brain Pathol. 2019; 30(3):541-553. PMC: 8018138. DOI: 10.1111/bpa.12801. View

11.

Cimino P, Holland E . Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas. Neuro Oncol. 2019; 21(6):819-821. PMC: 6556841. DOI: 10.1093/neuonc/noz052. View

12.

Parsons D, Jones S, Zhang X, Cheng-Ho Lin J, Leary R, Angenendt P . An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807-12. PMC: 2820389. DOI: 10.1126/science.1164382. View

13.

Louis D, Wesseling P, Paulus W, Giannini C, Batchelor T, Cairncross J . cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). Acta Neuropathol. 2018; 135(3):481-484. DOI: 10.1007/s00401-018-1808-0. View

14.

Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A . Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008; 116(6):597-602. DOI: 10.1007/s00401-008-0455-2. View

15.

Figarella-Branger D, Mokhtari K, Dehais C, Jouvet A, Uro-Coste E, Colin C . Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations. Neuro Oncol. 2014; 16(9):1244-54. PMC: 4136899. DOI: 10.1093/neuonc/nou047. View

16.

Appay R, Dehais C, Maurage C, Alentorn A, Carpentier C, Colin C . CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol. 2019; 21(12):1519-1528. PMC: 7145561. DOI: 10.1093/neuonc/noz124. View

17.

Capper D, Jones D, Sill M, Hovestadt V, Schrimpf D, Sturm D . DNA methylation-based classification of central nervous system tumours. Nature. 2018; 555(7697):469-474. PMC: 6093218. DOI: 10.1038/nature26000. View

18.

Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss D, Sahm F . Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol. 2018; 136(1):153-166. DOI: 10.1007/s00401-018-1849-4. View

19.

Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T . Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol. 2017; 20(1):66-77. PMC: 5761527. DOI: 10.1093/neuonc/nox132. View

20.

Reuss D, Mamatjan Y, Schrimpf D, Capper D, Hovestadt V, Kratz A . IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol. 2015; 129(6):867-73. PMC: 4500039. DOI: 10.1007/s00401-015-1438-8. View